Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
AstraZeneca
Baxter
Harvard Business School
Moodys

Last Updated: October 22, 2019

DrugPatentWatch Database Preview

Sun Pharm Inds Inc Company Profile

See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for SUN PHARM INDS INC, and what generic alternatives to SUN PHARM INDS INC drugs are available?

SUN PHARM INDS INC has eighty approved drugs.

There are eleven US patents protecting SUN PHARM INDS INC drugs. There is one tentative approval on SUN PHARM INDS INC drugs.

There are twenty-four patent family members on SUN PHARM INDS INC drugs in fifteen countries and ninety-three supplementary protection certificates in fifteen countries.

Summary for Sun Pharm Inds Inc
International Patents:24
US Patents:11
Tradenames:68
Ingredients:64
NDAs:80

Drugs and US Patents for Sun Pharm Inds Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharm Inds Inc ABSORICA isotretinoin CAPSULE;ORAL 021951-005 Aug 15, 2014 RX Yes No 8,952,064   Start Trial Y   Start Trial
Sun Pharm Inds Inc CARVEDILOL carvedilol TABLET;ORAL 077346-003 Sep 5, 2007 AB RX No No   Start Trial   Start Trial
Sun Pharm Inds Inc TRAMADOL HYDROCHLORIDE tramadol hydrochloride TABLET;ORAL 075964-001 Jun 19, 2002 AB RX No No   Start Trial   Start Trial
Sun Pharm Inds Inc ABSORICA isotretinoin CAPSULE;ORAL 021951-002 May 25, 2012 BX RX Yes No 8,952,064   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Sun Pharm Inds Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sun Pharm Inds Inc BACTRIM sulfamethoxazole; trimethoprim INJECTABLE;INJECTION 018374-001 Approved Prior to Jan 1, 1982 3,551,564   Start Trial
Sun Pharm Inds Inc XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-001 Jul 11, 2012 5,908,838   Start Trial
Sun Pharm Inds Inc XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-005 Jul 11, 2012 5,908,838   Start Trial
Sun Pharm Inds Inc ULTRAVATE halobetasol propionate CREAM;TOPICAL 019967-001 Dec 27, 1990 4,619,921   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for SUN PHARM INDS INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsules 25 mg ➤ Subscribe 2016-05-16
➤ Subscribe Capsules 20 mg ➤ Subscribe 2013-01-07
➤ Subscribe Capsules 35 mg ➤ Subscribe 2015-11-25
➤ Subscribe Capsules 30 mg and 40 mg ➤ Subscribe 2012-12-31
➤ Subscribe Capsules 20 mg ➤ Subscribe 2013-06-19

Supplementary Protection Certificates for Sun Pharm Inds Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1602370 SPC/GB09/024 United Kingdom   Start Trial PRODUCT NAME: COMBINATION COMPRISING ALISKIREN, AS THE FREE BASE OR AS A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND HYDROCHLOROTHIAZIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: CH 5893501 20081028; CH 5893502 20081028; CH 5893503 20081028; CH 5893504 20081028; UK EU/1/08/491/006 20090116; UK EU/1/08/491/002 20090116; UK EU/1/08/491/003 20090116; UK EU/1/08/491/004 20090116; UK EU/1/08/491/005 20090116; UK EU/1/08/491/007 20090116; UK EU/1/08/491/080 20090116; UK EU/1/08/491/074 20090116; UK EU/1/08/491/075 20090116; UK EU/1/08/491/076 20090116; UK EU/1/08/491/077 20090116; UK EU/1/08/491/078 20090116; UK EU/1/08/491/079 20090116; UK EU/1/08/491/068 20090116; UK EU/1/08/4
1532149 92128 Luxembourg   Start Trial PRODUCT NAME: 8-(3-AMINOPIPERIDIN-1-YL)-7-BUT-2-INYL-3-METHYL-1-(4-METHYLCHINAZOLIN-2-YLMETHYL)-3, 7-DIHYDROPURIN-2, 6-DION, LES ENANTIOMERES ET LEURS SELS, EN PARTICULIER LA LINAGLIPTINE COMBINEE AVEC DU CHLORHYDRATE DE METFORMINE. LINAGLIPTINE
2217577 122019000008 Germany   Start Trial PRODUCT NAME: DUZALLO - ALLOPURINOL / LESINURAD ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ ODER VERTRAEGLICHE SALZE DAVON; REGISTRATION NO/DATE: EU/1/18/1300 20180823
0443983 2007C/043 Belgium   Start Trial PRODUCT NAME: AMLODIPINE ET VALSARTAN; NATL. REGISTRATION NO/DATE: EU/1/06/370/001 20070118; FIRST REGISTRATION: CH 57771 20061222
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Boehringer Ingelheim
Medtronic
Harvard Business School
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.